Debt to Equity Ratio: 0.07
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.07 is 32% below its 5-year average of 0.10, near the low end of its 5-year range (0.07–0.15).
As of Sunday, June 28, 2026. 0.09% below its 12-month average of 0.07.
EW Debt to Equity Ratio
Reported quarterly debt to equity ratio; no daily interpolation.
EW Average Debt to Equity Ratio Chart
EW Current vs Average Debt to Equity Ratio Chart
EW Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.07
DEBT TO EQUITY RATIO AVG TTM
0.07
DEBT TO EQUITY RATIO AVG 3Y
0.09
DEBT TO EQUITY RATIO AVG 5Y
0.10
DEBT TO EQUITY RATIO AVG 10Y
0.17
DEBT TO EQUITY RATIO AVG 15Y
0.18
DEBT TO EQUITY RATIO AVG 20Y
0.19
CURRENT VS TTM AVG
-0.09%
CURRENT VS 3Y AVG
-19.95%
CURRENT VS 5Y AVG
-31.62%
CURRENT VS 10Y AVG
-60.69%
CURRENT VS 15Y AVG
-62.87%
CURRENT VS 20Y AVG
-64.09%
EW Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 0.07 | 0.07 | 0.09 | 0.10 |
| Cencora, Inc. (COR)vs › | $55.67B | 7.13 | 8.71 | 10.16 | 17.42 |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | -3.36 | 3.77 | 2.58 | 2.11 |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 0.76 | 0.79 | 0.73 | 0.74 |
| Humana Inc. (HUM)vs › | $46.08B | 0.73 | 0.74 | 0.75 | 0.72 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 0.67 | 0.65 | 1.10 | 1.25 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 0.09 | 0.09 | 0.10 | 0.13 |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 0.51 | 0.51 | 0.51 | 0.54 |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 0.50 | 0.55 | 0.53 | 0.52 |
| Medline Inc. (MDLN)vs › | $32.87B | 1.17 | 1.09 | 0.79 | 0.79 |
Financial Health
Debt/Equity
0.07
Current Ratio
3.72
Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The debt to equity ratio for EW stock is 0.07.
- Is Edwards Lifesciences Corporation's debt to equity ratio high or low?
- The debt to equity ratio of 0.07 is 32% below its 5-year average of 0.10, near the low end of its 5-year range (0.07–0.15).
- What is the TTM average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The TTM average debt to equity ratio for EW stock is 0.07.
- What is the 3Y average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The 3Y average debt to equity ratio for EW stock is 0.09.
- What is the 5Y average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The 5Y average debt to equity ratio for EW stock is 0.10.
- What is the 10Y average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The 10Y average debt to equity ratio for EW stock is 0.17.
- What is the 15Y average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The 15Y average debt to equity ratio for EW stock is 0.18.
- What is the 20Y average debt to equity ratio for Edwards Lifesciences Corporation (EW)?
- The 20Y average debt to equity ratio for EW stock is 0.19.
EW Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-03-31 | 0.07 |
| 2025-12-31 | 0.07 |
| 2025-09-30 | 0.07 |
| 2025-06-30 | 0.07 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | 0.07 |
| 2024-09-30 | 0.07 |
| 2024-06-30 | 0.09 |
| 2024-03-31 | 0.10 |
| 2023-12-31 | 0.10 |
| 2023-09-30 | 0.10 |
| 2023-06-30 | 0.11 |
| 2023-03-31 | 0.12 |
| 2022-12-31 | 0.12 |
| 2022-09-30 | 0.11 |
| 2022-06-30 | 0.11 |
| 2022-03-31 | 0.12 |
| 2021-12-31 | 0.12 |
| 2021-09-30 | 0.12 |
| 2021-06-30 | 0.13 |
| 2021-03-31 | 0.15 |
| 2020-12-31 | 0.15 |
| 2020-09-30 | 0.16 |
| 2020-06-30 | 0.18 |
| 2020-03-31 | 0.17 |
| 2019-12-31 | 0.16 |
| 2019-09-30 | 0.18 |
| 2019-06-30 | 0.19 |
| 2019-03-31 | 0.19 |
| 2018-12-31 | 0.19 |
| 2018-09-30 | 0.36 |
| 2018-06-30 | 0.38 |
| 2018-03-31 | 0.32 |
| 2017-12-31 | 0.35 |
| 2017-09-30 | 0.33 |
| 2017-06-30 | 0.35 |
| 2017-03-31 | 0.31 |
| 2016-12-31 | 0.31 |
| 2016-09-30 | 0.22 |
| 2016-06-30 | 0.24 |
| 2016-03-31 | 0.26 |
| 2015-12-31 | 0.24 |
| 2015-09-30 | 0.25 |
| 2015-06-30 | 0.26 |
| 2015-03-31 | 0.27 |
| 2014-12-31 | 0.27 |
| 2014-09-30 | 0.30 |
| 2014-06-30 | 0.31 |
| 2014-03-31 | 0.54 |
| 2013-12-31 | 0.38 |
| 2013-09-30 | 0.37 |
| 2013-06-30 | 0.14 |
| 2013-03-31 | 0.12 |
| 2012-12-31 | 0.13 |
| 2012-09-30 | 0.11 |
| 2012-06-30 | 0.13 |
| 2012-03-31 | 0.13 |
| 2011-12-31 | 0.11 |
| 2011-09-30 | 0.13 |
| 2011-06-30 | 0.13 |
| 2011-03-31 | 0.11 |
| 2010-12-31 | 0.03 |
| 2010-09-30 | 0.08 |
| 2010-06-30 | 0.16 |
| 2010-03-31 | 0.11 |
| 2009-12-31 | 0.08 |
| 2009-09-30 | 0.09 |
| 2009-06-30 | 0.11 |
| 2009-03-31 | 0.13 |
| 2008-12-31 | 0.20 |
| 2008-09-30 | 0.23 |
| 2008-06-30 | 0.16 |
| 2008-03-31 | 0.27 |
| 2007-12-31 | 0.25 |
| 2007-09-30 | 0.26 |
| 2007-06-30 | 0.26 |
| 2007-03-31 | 0.29 |
| 2006-12-31 | 0.31 |
| 2006-09-30 | 0.35 |
| 2006-06-30 | 0.39 |
| 2006-03-31 | 0.40 |
| 2005-12-31 | 0.46 |
| 2005-09-30 | 0.38 |
| 2005-06-30 | 0.41 |
| 2005-03-31 | 0.43 |
| 2004-12-31 | 0.43 |
| 2004-09-30 | 0.45 |
| 2004-06-30 | 0.53 |
| 2004-03-31 | 0.59 |
| 2003-12-31 | 0.40 |
| 2003-09-30 | 0.51 |
| 2003-06-30 | 0.55 |
| 2003-03-31 | 0.51 |
| 2002-12-31 | 0.46 |
| 2002-09-30 | 0.61 |
| 2002-06-30 | 0.62 |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian